Nine ProShares ETFs Added to TD Ameritrade’s ETF Market Center’s Commission-Free Menu
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Business Wire
BETHESDA, Md.--(BUSINESS WIRE)-- ProShares, a premier provider of ETFs, today announced the inclusion of nine more of its ETFs to the TD Ameritrade ETF Market Center’s menu of commission-free funds. The new ProShares ETFs include dividend growth, fixed income and funds focusing on global trends. They also include the first geared (inverse) ETF offering on the platform. “Commission-free ETF trading is becoming more critical as investors of all types prioritize cost efficiency. Advisors and investors can now access some of our largest and most popular ETFs without transaction fees,” said Steve Cohen, managing director at ProShares. “We’re delighted to expand our relationship with TD Ameritrade, and to improve the accessibility of these funds to one of the largest and fastest-growing custodians in the marketplace serving registered investment advisors (RIAs) and individual investors.” T
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)GlobeNewswire
- Zenas BioPharma to Participate in Upcoming Healthcare Investor ConferencesGlobeNewswire
- Zenas Bio: Recent IPO With Late-Stage Candidate [Seeking Alpha]Seeking Alpha
ZBIO
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- 12/4/24 - Form 4
- ZBIO's page on the SEC website